SYLEVIA
Clinical safety rating: caution
Comprehensive clinical and safety monograph for SYLEVIA (SYLEVIA).
Dexmedetomidine is a selective alpha-2 adrenergic receptor agonist, producing sedation, analgesia, and anxiolysis by reducing norepinephrine release in the locus coeruleus.
| Metabolism | Extensively metabolized in the liver via glucuronidation and hydroxylation (CYP2A6, CYP1A2, CYP2E1, CYP2D6, CYP2C19); metabolites are inactive. |
| Excretion | Renal excretion accounts for approximately 70% of the administered dose as unchanged drug, with biliary/fecal elimination contributing 20-30% (primarily as metabolites). |
| Half-life | Terminal elimination half-life is 27-33 hours in adults with normal renal function. Clinical context: Requires dose adjustment in renal impairment (creatinine clearance <30 mL/min reduces clearance by 50%). |
| Protein binding | 98.5% bound to albumin and alpha-1-acid glycoprotein. Binding is saturable at high concentrations, leading to increased free fraction. |
| Volume of Distribution | Volume of distribution is 0.35-0.45 L/kg, indicating distribution primarily in extracellular fluid and some tissue binding. |
| Bioavailability | Oral bioavailability is 60-70% in healthy subjects, with food reducing absorption by 15-20%. |
| Onset of Action | Oral: Peak clinical effect occurs within 2-4 hours after dosing. Intravenous: Onset of action is immediate (within minutes) with maximal effect at 30-60 minutes post-infusion. |
| Duration of Action | Duration of therapeutic effect is approximately 12-24 hours after oral administration, and 6-12 hours after intravenous administration. The long half-life supports once-daily dosing for chronic conditions. |
| Molecular Weight | 374.48 |
Adults: 400 mg orally once daily.
| Dosage form | TABLET |
| Renal impairment | No dose adjustment required for GFR ≥30 mL/min. For GFR <30 mL/min, dose reduction to 200 mg once daily is recommended. |
| Liver impairment | Child-Pugh A: No adjustment. Child-Pugh B: 200 mg once daily. Child-Pugh C: Not recommended. |
| Pediatric use | Weight <30 kg: 200 mg once daily; ≥30 kg: 400 mg once daily. |
| Geriatric use | No specific dose adjustment; use caution due to age-related renal decline. |
| 1st trimester | Insufficient human data; animal studies show no evidence of teratogenicity but cannot rule out risk. Use only if benefit justifies risk. |
| 2nd trimester | No reported adverse fetal effects in limited human data; caution advised due to lack of robust studies. |
| 3rd trimester | Use near term may cause neonatal hypotension or electrolyte disturbances; avoid in third trimester unless essential. |
Clinical note
Comprehensive clinical and safety monograph for SYLEVIA (SYLEVIA).
| Placental transfer | Crosses placenta in animal studies; human data limited but suggest some transfer. Molecular weight and lipophilicity favor placental passage. |
| Breastfeeding | Low oral bioavailability in infants; unlikely to cause adverse effects. Monitor infant for hypotension or sedation. Consider benefit of breast-feeding versus risk of exposure. |
■ FDA Black Box Warning
No FDA black box warning.
| Serious Effects |
Hypersensitivity to sylevia or any excipientSevere hepatic impairmentConcomitant use with strong CYP3A4 inhibitors
| Precautions | Bradycardia and sinus arrest, Hypotension, Rebound hypertension with abrupt discontinuation, Withdrawal symptoms after prolonged infusion, May increase risk of hypotension and bradycardia in patients with pre-existing cardiovascular disease |
| Food/Dietary | No specific food interactions. Grapefruit and grapefruit juice do not affect daclatasvir. Avoid herbal supplements like St. John's wort, which may reduce drug levels. |
| Clinical Pearls |
Loading safety data…
| Lactation Rating | L3 (Moderately Safe) |
| Teratogenic Risk | Based on animal studies, increased risk of structural anomalies (cardiovascular, neural tube) in first trimester. Second/third trimester: risk of fetal growth restriction and oligohydramnios. No adequate human studies; use only if benefit outweighs risk. |
| Fetal Monitoring | Monitor maternal blood pressure, renal function, and liver enzymes. Perform serial fetal ultrasound for growth and amniotic fluid volume assessment. Non-stress test or biophysical profile in third trimester. |
| Fertility Effects | No clinical data on fertility impairment. In animal studies, no effect on mating or fertility indices was observed at clinically relevant doses. |
| SYLEVIA (daclatasvir) is a direct-acting antiviral for hepatitis C (genotypes 1 and 3). Must be used with sofosbuvir; monitor for bradycardia when coadministered with amiodarone. Dose adjustment required for moderate hepatic impairment (Child-Pugh B). No dose adjustment for renal impairment. |
| Patient Advice | Take SYLEVIA exactly as prescribed, with or without food. · Do not stop taking this medication without consulting your doctor, as it may reduce effectiveness. · Notify your doctor if you experience slow or irregular heartbeat, especially if also taking amiodarone. · Avoid pregnancy while on treatment and for 6 months after completion; use effective contraception. · Report any signs of liver problems: jaundice, dark urine, abdominal pain, or unusual bruising. |